A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.

A transfer device for a living organism for placing an object in a living organism comprises a plurality of movable units. Each movable unit comprises one or more needles extending in a first direction. Each needle has a cylindrical shape capable of storing the object therein. Each movable unit is movable in the first direction.

A method of producing a caffeic acid phenethyl ester loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer. The method includes seeding a plurality of skin stem cells in a medium; enabling the plurality of skin stem cells in the medium to reach a confluency of 70-80% to be seeded in a plurality of culture plates; preparing a caffeic acid phenethyl ester stock solution by dissolving the caffeic acid phenethyl ester in dimethyl sulfoxide DMSO; performing a microvesicle isolation from specialized skin cells; adding the caffeic acid phenethyl ester into a plurality of microvesicles; and separating the caffeic acid phenethyl ester loaded microvesicles from the caffeic acid phenethyl ester which is free in the solution and not loaded to a microvesicle.

A method of improving integration and/or functionality of gonadal organoids introduced to a subject includes the steps of pre-treating the subject with a chorionic gonadotrophin (CG), administering a therapeutically effective amount of the gonadal organoids to the subject, and administering the CG to the subject over time post-treatment to maintain LHCG receptor expression and signaling.

A method of improving integration and/or functionality of gonadal organoids introduced to a subject includes the steps of pre-treating the subject with a chorionic gonadotrophin (CG), administering a therapeutically effective amount of the gonadal organoids to the subject, and administering the CG to the subject over time post-treatment to maintain LHCG receptor expression and signaling.

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×10.sup.5 CD3.sup.+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×10.sup.6 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×10.sup.5 CD3.sup.+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×10.sup.6 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×10.sup.5 CD3.sup.+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×10.sup.6 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of the extract for preventing or treating cancer, or the use of the extract for stimulating secretion of cytokine by somatic cells in a patient. In addition, the present invention also relates to a drug combination comprising the extract as the first anticancer agent and a second anticancer agent as well as its use for preventing or treating cancer.

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of the extract for preventing or treating cancer, or the use of the extract for stimulating secretion of cytokine by somatic cells in a patient. In addition, the present invention also relates to a drug combination comprising the extract as the first anticancer agent and a second anticancer agent as well as its use for preventing or treating cancer.